However, when the MGMT promoter is methylated, alkylating agents are more potent (Methylguanine-DNA methyltransferase (MGMT)|Radiology Reference Article|Radiopaedia.org 2022). It has been examined as a potential biomarker of susceptibility to alkylating chemotherapy, particularly temozolomide (TMZ), because of its relatively high frequency in GBM, which may vary depending on the method employed for its assessment (Stupp et al. May 2009). Here, MGMT is linked to glioblastoma.